The jury’s ruling comes just days after a subsidiary of Johnson & Johnson, known as LTL Management, filed a lawsuit against multiple physicians for publishing separate research linking its talcum powder to mesothelioma, specifically.
The company has so far in that lawsuit claimed that the physicians’ research is a “house of cards [that] is collapsing as the truth comes to light.”
While it’s unclear how Johnson & Johnson’s lawsuit against the physicians will move forward, the California patient’s victory may make it more unlikely for other patients who experienced the same circumstances to accept settlements that were previously offered to them by J&J, according to the Times.
“This verdict will sway people not to be inclined to accept what they can get under that $8.9-billion settlement if they can get $18 million at trial,” said Carl Tobias, a University of Richmond (Va.) law professor, told the Times. “This is not good for J&J, to be sure. It may discombobulate the settlement negotiations.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.